DE602005001299D1 - Kombinationen von Markern zum Nachweis von typ 1 und 2 Diabetes - Google Patents

Kombinationen von Markern zum Nachweis von typ 1 und 2 Diabetes

Info

Publication number
DE602005001299D1
DE602005001299D1 DE602005001299T DE602005001299T DE602005001299D1 DE 602005001299 D1 DE602005001299 D1 DE 602005001299D1 DE 602005001299 T DE602005001299 T DE 602005001299T DE 602005001299 T DE602005001299 T DE 602005001299T DE 602005001299 D1 DE602005001299 D1 DE 602005001299D1
Authority
DE
Germany
Prior art keywords
markers
risk
cardiovascular complication
suffering
diabetes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005001299T
Other languages
English (en)
Other versions
DE602005001299T2 (de
Inventor
Georg Hess
Andrea Horsch
Werner Poppe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Roche Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics GmbH filed Critical Roche Diagnostics GmbH
Publication of DE602005001299D1 publication Critical patent/DE602005001299D1/de
Application granted granted Critical
Publication of DE602005001299T2 publication Critical patent/DE602005001299T2/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/471—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
DE602005001299T 2004-07-07 2005-07-05 Kombinationen von Markern zum Nachweis von typ 1 und 2 Diabetes Active DE602005001299T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04015936 2004-07-07
EP04015936 2004-07-07

Publications (2)

Publication Number Publication Date
DE602005001299D1 true DE602005001299D1 (de) 2007-07-19
DE602005001299T2 DE602005001299T2 (de) 2008-02-07

Family

ID=35589257

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005001299T Active DE602005001299T2 (de) 2004-07-07 2005-07-05 Kombinationen von Markern zum Nachweis von typ 1 und 2 Diabetes

Country Status (6)

Country Link
US (2) US20060019315A1 (de)
JP (1) JP4488968B2 (de)
AT (1) ATE364177T1 (de)
CA (1) CA2511649A1 (de)
DE (1) DE602005001299T2 (de)
ES (1) ES2288718T3 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1882945A1 (de) * 2006-07-28 2008-01-30 F.Hoffmann-La Roche Ag Vorrichtungen und Verfahren zur Differentierung zwischen herz- und lungenbedingten Ursachen für akute Atemnot
DE602006015964D1 (de) * 2006-09-20 2010-09-16 Roche Diagnostics Gmbh Natriurethische Peptide und Plazenta-Wachstumfaktor/löslicher VEGF-Rezeptor unterscheiden zwischen mit der Plazenta verbundener Herzdysfunktion und mit Herzerkrankung verbundener Herzdysfunktion
WO2008046213A1 (en) * 2006-10-18 2008-04-24 Axela Inc. Measuring multiple analytes over a broad range of concentrations using optical diffraction
WO2009004443A2 (en) * 2007-07-04 2009-01-08 Medizinische Universität Wien Compositions for the detection of gene expression in diabetic microangiopathy
EP2037277A1 (de) * 2007-09-11 2009-03-18 F. Hoffmann-La Roche AG Verfahren zum Testen der funktionalen Integrität und der Qualität einer Blutplättchenprobe
EP2090891A1 (de) * 2008-02-13 2009-08-19 F.Hoffmann-La Roche Ag Mittel und Verfahren zur Bestimmung der atherosklerotischen Last unter Verwendung von Biomarker-PLGF
JP2011523072A (ja) * 2008-06-13 2011-08-04 エフ．ホフマン−ラ ロシュ アーゲー １型糖尿病を有する患者の合併症の評価
WO2009150249A1 (en) * 2008-06-13 2009-12-17 Roche Diagnostics Gmbh Nt-probnp as prognostic indicator for the development of end stage renal disease in diabetes mellitus
BR112012018771A2 (pt) * 2010-01-29 2017-06-20 Metanomics Gmbh ''método para dianosticar insuficência cardíaca em um sujeito''
US20140324460A1 (en) * 2012-09-26 2014-10-30 Health Diagnostic Laboratory, Inc. Method for determining and managing total cardiodiabetes risk
EP2843415B1 (de) * 2013-08-30 2020-04-01 LURIC Datenbank GbR Verfahren für die Beurteilung des kardiovaskulären Risikos bei Diabetikern
US12001939B2 (en) 2018-12-11 2024-06-04 Eko.Ai Pte. Ltd. Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views
US11446009B2 (en) 2018-12-11 2022-09-20 Eko.Ai Pte. Ltd. Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images
US11931207B2 (en) 2018-12-11 2024-03-19 Eko.Ai Pte. Ltd. Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device
FR3109999B1 (fr) * 2020-05-05 2024-06-14 Francais Du Sang Ets Methode de detection de l’activation plaquettaire liee a l’inflammation
JP7440093B2 (ja) * 2021-03-15 2024-02-28 株式会社カルナヘルスサポート 末期腎不全発症予測方法
CN114609395B (zh) * 2022-04-25 2024-03-29 李玉凤 一种预测或诊断糖尿病或糖尿病肾病患者中的早期动脉粥样硬化的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1625163T3 (da) * 2003-05-12 2011-12-05 Hoffmann La Roche Fremgangsmåde til at påvise proBNP med en monoklonal antistofbinding til aminosyrerne 38-43
WO2005042795A2 (en) * 2003-10-31 2005-05-12 Queststar Medical, Inc. Plasma polymerization of atomically modified surfaces
DK1882946T3 (da) * 2003-12-23 2010-05-31 Hoffmann La Roche Fremgangsmåde til at bedømme rheumatold arthritis ved at måle anti-CCP og interleukin 6

Also Published As

Publication number Publication date
DE602005001299T2 (de) 2008-02-07
ATE364177T1 (de) 2007-06-15
ES2288718T3 (es) 2008-01-16
CA2511649A1 (en) 2006-01-07
JP2006030182A (ja) 2006-02-02
JP4488968B2 (ja) 2010-06-23
US20060019315A1 (en) 2006-01-26
US20070015208A1 (en) 2007-01-18

Similar Documents

Publication Publication Date Title
DE602005001299D1 (de) Kombinationen von Markern zum Nachweis von typ 1 und 2 Diabetes
ATE373827T1 (de) Kombination von markern für diabetes typ 1 und 2
PT1849009E (pt) Utilização de hormonas cardíacas para avaliar um risco cardiovascular em relação à administração de fármacos anti-inflamatórios
CN101568833B (zh) 使用MR-proADM的糖尿病诊断和风险分级
ATE403157T1 (de) Verwendung des bnp-art und anp-art peptiden für das festsetzen der gefahren von herzgefäss- komplikationen als folge der volumenüberlastung
Fitzpatrick et al. Parathyroid hormone and the cardiovascular system
JP2010513879A5 (de)
CA2567738A1 (en) The use of cardiac hormones for diagnosing the risk of suffering from a cardiovascular complication as a consequence of cardiotoxic medication
JP2008046129A5 (de)
CN101636657A (zh) 借助于利尿肽对nyhai级患者进行心功能不全的诊断和危险分层
JP5190067B2 (ja) Ｎｔ−プロｂｎｐと組み合わせてのｃｔ−プロｅｔ−１による急性冠症候群の診断および危険性の分類
WO2004046194A3 (en) Polyclonal-monoclonal elisa assay for detecting n-terminus probnp
JP2013508707A5 (de)
RU2014136453A (ru) Биомаркеры для диагностики, прогноза, оценки и стратификации терапии обмороков
EP1995596A1 (de) Mittel und Verfahren zum Beurteilen von Herzinsuffizienz bei Patienten mit Vorhofflimmern mittels GDF-15 und natriuretischer Peptide
DK1644740T3 (da) Vurdering af skeletal vækst ved anvendelse af målinger af NT-CNP-peptider
Ma et al. Plasma pituitary adenylate cyclase-activating polypeptide concentrations and mortality after acute spontaneous basal ganglia hemorrhage
EP2496946B1 (de) NT-pro-ANP und sFlt-1 zur Differenzierung zwischen Kreislauf- und Ischämiereignissen
ATE476665T1 (de) Natriurethische peptide und plazenta- wachstumfaktor/löslicher vegf-rezeptor unterscheiden zwischen mit der plazenta verbundener herzdysfunktion und mit herzerkrankung verbundener herzdysfunktion
JP2010511877A5 (de)
RU2012115125A (ru) Мультимаркерная панель для гипертрофии левого желудочка
EP1533619A3 (de) Spezifische Marker für Stoffwechselssyndrome
ES2657087T3 (es) Monitorización de péptidos natriuréticos cardiacos durante el diagnóstico, manejo y tratamiento de enfermedades cardiacas
CN203858247U (zh) 一种n-端脑钠肽前体检测试纸条
RU2015133019A (ru) Способ прогнозирования риска развития рака или диагностирования рака у индивидуума

Legal Events

Date Code Title Description
8364 No opposition during term of opposition